

Commissioning of Urology Services?

Di Riley



Developing the NHS Commissioning Board



"The purpose of the Board will be to use the £80bn commissioning budget to secure the best possible outcomes for patients."

This can be done by:

- Supporting local clinical improvement
- Transforming the management of long-term conditions
- Providing more services outside hospital settings
- Providing a more integrated system of urgent and emergency care to reduce the rate of growth in hospital admissions

NHS Commissioning Board



- Clinical Commissioning Advisory Groups:
 - Cancer (chair Sean Duffy)
 - Radiotherapy (chair Nick Slevin)
 - Radiosurgery also National Stereotactic RT consortium group (chair Matthew Hatton)

Cancer Networks



Using information to improve quality & choice

- Ministerial support for cancer networks but recognition that they have been of variable quality and effectiveness
- McLean Review of Clinical Networks (wider than cancer e.g. Cardiac) recently published
- Establishment of Specialist Clinical Networks (~15)
 - likely reduction of management support
 - greater emphasis on clinical leadership
- Likely to play a major role in commissioning at local level (link to specialist advice to Cancer Commissioning Boards – GPs)

Health & Well-being Boards



- Local authority chaired
- Bringing together primary & secondary care with public health and local authorities
- Heavy lay involvement
- May play an important role in public awareness campaigns in future

Quality drivers



- National Guidance (NICE, etc.)
- NICE Quality Standards
- Commissioning Outcome Framework indicators
- CQUINs (at Trust level)
- National Cancer Action Team & NCIN Service Profiles and Service Specifications (Specialist H&N Cancer MDT Service under development)
- 'Third Sector' (charities, etc) & public pressure

Levels of Commissioning



- National level (<500 incidence)
- Specialized Commissioning Groups (~7.5m pop)
- Clinical Commissioning Groups (local)

Commissioning Support Packs



Using information to improve quality & choice

KEY MESSAGES

www.cancertoolkit.co.uk

SERVICE PROFILES

SERVICE SPECIFICATION

Key messages on cancer (1)



Using information to improve quality & choice

- **1. The Incidence is rising:** 250,000 new cases p.a. now; 300,000 by 2030
- 2. Cancer services and outcomes (survival and mortality) have improved over the past 10–15 years. Much of the improvement has been in the hospital sector (MDTs etc)

Key messages on cancer (2)



- 3. Despite this, survival for many cancers remains poor in comparison with other developed countries
 - 5,000 lives a year could be saved if we matched the European average (renal -350, bladder - 145)
 - 10,000 lives a year could be saved if we achieved the level of the best (renal -700, bladder - 290)
- 4. Late diagnosis is the major factor underlying the poor survival rates in this country

Key messages on cancer (3)



- 5. This is not simply a matter of patients living a few extra months.
 - Life to years, not years to life!
 - It can often be the difference between early death and long term survival/cure
- 6. Initiatives to promote early diagnosis are likely to be highly cost effective

Key messages on cancer (4)



Using information to improve quality & choice

7. Particular attention should be given to:

- Reducing emergency presentations (23% of all cancers) as these have very poor survival
- The elderly who often present late
- Ensuring that providers record staging and report this to their cancer registry

Routes to Diagnosis



Using information to improve quality & choice

All Persons	Screen detected	Two Week Wait	GP referral	Other outpatient	Emergency presentation	Unknown	Number of patients
Bladder		32%	28%)	15%	18%	4%	7,665
Brain & CNS		1%	17%	14%	58%	6%	4,147
Breast	21%	42%	12%	9%	4%	12%	34,232
Kidney		20%	29%	18%	24%	6%	5,172
Lung		22%	20%	13%	38%	5%	29,420
Prostate		20%	38%	16%	9%	14%	28,362
Testis		48%	14%	16%	10%	10%	1,569

RtD – 1 yr survival



Using information to improve quality & choice

All Persons	All routes	Two Week Wait	GP referral	Other o/p	Emergency
Bladder	72%	82%	81%	75%	35%
Brain & CNS	44%	51%	60%	66%	32%
Breast	97%	98%	96%	97%	53%
Kidney	66%	81%	81%	77%	33%
Lung	26%	36%	39%	41%	9%
Prostate	95%	97%	99%	98%	54%
Testis	98%	100%	98%	98%	89%

Service Specifications



- These may be by pathway or clinical speciality
- Services may be commissioned locally or by Specialist Commissioning groups
- Challenge different commissioners?
 - Prevention & awareness local
 - Diagnostics local
 - Treatment local, specialist, national
 - Rehabilitation local
 - Supportive & palliative care local
- Specialist Urology Services specification under disc.

Key Service Outcomes



- Participation in National Audits
- Cancer waiting times
- Threshold for number of procedures, resection rates
- Length of stay/ readmission rates
- Recruitment into trials
- 30 day mortality, 1 & 5 year survival
- Registry data submissions esp. staging
- National Cancer Patient Experience Survey

Service Profiles – what are they?



- One strand of commissioning support.
- Trust level information for commissioners
- A wide range of information from multiple sources to support the Service Specification
- Issue for urology local and specialist services as per the IOG (still under discussion)
 - Penile, testicular
 - Radical Rx bladder, prostate

Service Profiles – supporting commissioning



- Using information to improve quality & choice
- Collate a range of information in one place.
- Define indicators in a well-documented and clinically robust way.
- Provide site-specific information tied-in to relevant guidance.
- Allow easy comparison across the 'providers'.
- Allow comparison to national benchmarks.

Targeted cancerprofiles



Jo Bloggs NHS Trust	Select Trust/MDT Lowest Eng. 25th Eng. Eng. 7 In Eng. Percentile mean Percent		Andrewstern to empresse guardin	g-d offense
	Proportion or rate Trust rates or proportion compare		1	
	No. of Lower Upper	o to England moun		
Section # Indicator	patients/ 95% 95% cases or Trust confide confide England Range			l
	cases or rouse confide		Source	Peri
Size 1 Number of new patients treated per year	200			
	50 500 400 500	100% (Cancer waits	2010
8	89 89% 86% 92% 94% 0%	100%	elic	ento
Patients with a registered cancer stage	15 15% 15% 15% 16% 0%	100%		-
6 Male patients	Quintile 2 17% 16% 18% 18% 0%	100%		
7 Patients with a registered cancer stage	2 204 204	100%		
	70 70% 50% 70%	100%		
	40 40% 30%	100%		
	34 3494 2394 4070 0%	100%		
	Yes 33% 38% 0%	100%		
12 Peer review: are there immediate risks?	82%			
	No 0%	100%		
	No 0%	100%		
	92 92% 90% 0%	100%		
16 Number of two week wait referrals for cancer	4 429 95% 99% 0%	100%		
17 Number and proportion of admission of the state of the	42 40% 39% 41% 45% 0%	100%	_	
17 Number and proportion of admissions that are emergencies 18 Patients referred via the screening service	100	100%		
19 / WW referrals with	47% 49% 52%		\rightarrow	
20 TWW referrals treated within 62 days	17% 16% 1994 1994	100%		
21 WW referrale dia-	85% 91% 92%	100%		
Patients treated within 24	41 98% 95% 101%	100%		
Surgical cases to it is a days of agreeing treatment plan	7 7% 7% 70% 103% 0%	100%		
Patiente	91 91% 90% 14% 0%	100%		
Patients und	12 129 94% 93% 0%			
ean locate and major surgical resection	0 12/0 12% 2104 004	100%		
and length of stay for elective admissions	20 8% 8% 16%	100%		
an length of stay for elective admissions an length of stay for emergency admissions iical patients readmitted as an	23 32% 31% 33% 20%	100%		
ical patients readmitted as an	4.5 44 46 90%	100%		
o follow up	5.7 5.5 4.6 0			
	4 404 5.9 5.7	100%		
net one year	4% 4% 1000	10		
patients who die within 30 days reporting being treated with respect and dignity tient experience survey questions	74% 7904	10		
reporting being treated with an	90% 87% 000	1000		
tient experience sugar 1	1% 91% 0%	100%		
ent experions	92% 1% 1% 0%	100%		
reporting being treated with respect and dignity tient experience survey questions scored as "green" gent experience survey questions scored as "green"		100%		
tent experience survey questions scored as "green" 3 ent experience survey questions scored as "red"	87%			
6	4%	100%		
	1	100%		
	0%			Y
		100%		
		100%		

Cancer Service Profiles for Breast Cancer

Data displayed are for patients for which the trust of treatment can be identified. For a full description of the data and methods please refer to the 'Data Defintions' document. For advice on how to use the profiles and the consultation, please refer to 'Profiles guidance'. Please direct comments/feedback to service.profiles@ncin.org.uk

Trust is significantly different from England mean
 Trust is not significantly different from England mean
 Statistical significance cannot be assessed

England mean

Highest in England 25th 75th Lowest in England

National Cancer Action Team

Section # Indicator Indicator Indicat			
Section # Indicator			
Size 2 Number of newly diagnosed patients treated per year, 2009 124	High- est	Source I	Period
2 Number of newly diagnosed patients treated per year, 2009 3 Patients aged 70+ 4 Patients with recorded ethnicity 5 Patients with recorded ethnicity which is not White-British 2 2 % 0% 6% 9% 0% 6 Patients who are Income Deprived (1) 7 Male patients 8 Patients with a nationally registered Nottingham Prognostic Index (NPI) 9 Patients with a nationally registered NPI in excellent or good prognostic groups 10 Patients with Charlson co-morbidity index >0 (to be included in later profile release) 11 Does the specialist team have full membership? (2) 12 Proportion of peer review are there immediate risks? (3) 15 CPES (4): Patients surveyed and % reporting being given name of a CNS (5.6) 16 Surgeons not managing 30+ cases per year 19 Reference of the patients with cases per year 11 25% 5% 70% 40% 0%	759	CWT 2010	0/11
4 Patients with recorded ethnicity 5 Patients with recorded ethnicity which is not White-British 5 Patients with recorded ethnicity which is not White-British 6 Patients with a recorded ethnicity which is not White-British 7 Male patients which a recorded ethnicity which is not White-British 8 Patients with a nationally registered Nottingham Prognostic Index (NPI) 9 Patients with a nationally registered NPI in excellent or good prognostic groups 10 Patients with Charlson co-morbidity index >0 (to be included in later profile release) 11 Does the specialist team have full membership? (2) 12 Proportion of peer review indicators met 13 Peer review: are there immediate risks? (3) 14 Peer review: are there immediate risks? (3) 15 CPES (4): Patients surveyed and % reporting being given name of a CNS (5.6) 16 Surgeons not managing 30+ cases per year 17 Surgeons not managing 30+ cases per year 18 Surgeons not managing 30+ cases per year 19 Surgeons not managing 30+ cases per year 19 Section of the patients with recorded ethnicity which is not White-British 2 2% 0% 6% 9% 0% 14 Patients with recorded ethnicity which is not White-British 2 2% 0% 6% 9% 0% 14 Patients with recorded ethnicity which is not White-British 2 2% 0% 6% 9% 0% 14 Patients with recorded ethnicity which is not White-British 2 2% 0% 6% 9% 0% 14 Patients with recorded ethnicity which is not White-British 2 2% 0% 6% 9% 0% 14 Patients with recorded ethnicity which is not White-British 1 2 2% 0% 0% 6% 9% 0% 1 4 Patients with a nationally registered NPI in excellent (NPI) 1	754	CWT/NCDR 2009	9
10 Patients with Chairson co-morbidity index >0 (to be included in later profile release) 11 Does the specialist team have full membership? (2) PR Yes 12 Proportion of peer review indicators met PR 91% 76%	57%	CWT/NCDR 2009	9
10 Patients with Chairson co-morbidity index >0 (to be included in later profile release) 11 Does the specialist team have full membership? (2) PR Yes 12 Proportion of peer review indicators met PR 91% 76%	99%	CWT/NCDR 2009	9
Patients with Charison co-morbidity index >0 (to be included in later profile release) 11 Does the specialist team have full membership? (2) PR Yes 12 Proportion of peer review indicators met PR 91% Specialist Peer review: are there immediate risks? (3) PR No 14 Peer review: are there serious concerns? (3) PR Yes 15 CPES (4): Patients surveyed and % reporting being given name of a CNS (5,6) PR Yes 16 Surgeons not managing 30+ cases per year 1 25% PN 40%	71%	CWT/NCDR 2009	9
10 Patients with Chairson co-morbidity index >0 (to be included in later profile release) 11 Does the specialist team have full membership? (2) PR Yes 12 Proportion of peer review indicators met PR 91% 76%	O 29%	CWT/NCDR 2009	9
10 Patients with Chairson co-morbidity index >0 (to be included in later profile release) 11 Does the specialist team have full membership? (2) PR Yes 12 Proportion of peer review indicators met PR 91% 76%	2%	CWT/NCDR 2009	9
10 Patients with Chairson co-morbidity index >0 (to be included in later profile release) 11 Does the specialist team have full membership? (2) PR Yes 12 Proportion of peer review indicators met PR 91% 76%	88%	CWT/NCDR 2009	9
10 Patients with Chairson co-morbidity index >0 (to be included in later profile release) 11 Does the specialist team have full membership? (2) PR Yes 12 Proportion of peer review indicators met PR 91% 76%	73%	CWT/NCDR 2009	-
Specialist Team 12 Proportion of peer review indicators met 13 Peer review: are there immediate risks? (3) 14 Peer review: are there serious concerns? (3) 15 CPES (4): Patients surveyed and % reporting being given name of a CNS (5.6) 16 Surgeons not managing 30+ cases per year 17 Proportion of peer review indicators met 18 PR 19 91% 19 PR 10 PR		CWT/NCDR 2009	9
Specialist Team 13 Peer review: are there immediate risks? (3) 14 Peer review: are there serious concerns? (3) 15 CPES (4): Patients surveyed and % reporting being given name of a CNS (5.6) 16 Surgeons not managing 30+ cases per year 1		NCPR 2010	0/11
Team 14 Peer review: are there serious concerns? (3) PR Yes 94% 73% 15 CPES (4): Patients surveyed and % reporting being given name of a CNS (5.6) n/a n/a 94% 73% 16 Surgeons not managing 30+ cases per year 1 25% 5% 70% 40% 0%		NCPR 2010	0/11
15 CPES (4): Patients surveyed and % reporting being given name of a CNS (5,6) n/a n/a 94% 73% 16 Surgeons not managing 30+ cases per year 1 25% 5% 70% 40% 0%		NCPR 2010	0/11
16 Surgeons not managing 30+ cases per year 1 25% 5% 70% 40% 0%		NCPR 2010	0/11
	100%	CPES 2010	
	80%		9/10
17 Number of urgent GP referrals for suspected cancer 1,299 307	4,126	CWT 2010	0/11
18 Patients with invasive cancer and treated at this trust 168 99% 97% 100% 92% 52%	100%	CWT 2010	0/11
Throughput 19 Patients with non-invasive cancer and treated at this trust 1 1% 0% 3% 8% 0%	48%	CWT 2010	0/11
20 Episodes following an emergency admission (new and existing cancers) 167 55% 49% 60% 37% 10%	71%	HES 2009	9/10
21 Patients referred via the screening service 3 2% 1% 7% 33% 0% 0	64%	WMCIU 2009	9
22 Q2 2011/12: Urgent GP referral for suspected cancer seen within 2 weeks 306 99% 97% 100% 97% 68%	100%	CWT 2011	1/12 Q2
23 Q2 2011/12: Treatment within 62 days of urgent GP referral for suspected cancer 27 100% 88% 100% 97% 86%	100%	CWT 2011	1/12 Q2
Waiting 24 Urgent GP referrals for suspected cancer diagnosed with cancer (to be included in later		CWT 2010	0/11
times 25 Cases treated that are urgent GP referrals with suspected cancer profile release)		CWT 2010	0/11
26 Q2 2011/12: First treatment began within 31 days of decision to treat 48 100% 93% 100% 99% 88%	100%	CWT 2011	1/12 Q2
27 Q2 2011/12: Urgent breast symptom referrals (cancer not suspected) seen in 2 wks 316 99% 98% 100% 96% 61%	100%	CWT 2011	1/12 Q2
28 Surgical cases receiving sentinel lymph node biopsy 84 55% 47% 63% 43% 0%	76%	HES 2010	0/11
29 Day case or one overnight stay surgery 134 74% 67% 79% 72% 28%	96%	HES 2010	0/11
30 Mastectomy patients receiving immediate reconstruction 17 23% 15% 34% 19% 0%	73%	HES 2010	0/11
Practice 31 Major surgeries in breast cancer patients (including in-situ cases) 98 79% 71% 85% 74% 50%	87%	HES/NCDR 2009	9
32 Surgical patients receiving mastectomies 72 52% 44% 60% 39% 22%	69%	HES 2009	9/10
33 Mean length of episode for elective admissions 2.4 2.8 0.7	6.3		9/10
34 Mean length of episode for emergency admissions 4.7 4.9 2.4	11.3	HES 2009	9/10
Outcomes 35 Surgical patients readmitted as an emergency within 28 days 7 4% 2% 8% 4% 1%	15%	HES 2010	0/11
and 36 Q2-Q4 2010/11: First outpatient appointments of all outpatient appointments 3,654 41% 40% 42% 43% 23%	71%	PBR SUS 2010	0/11 Q2-Q4
Recovery 37 Patients treated surviving at one year (to be included in later profile release)			
Patient 38 Patients surveyed & % reporting always being treated with respect & dignity (6) n/a n/a 82% 65%			0
Experience - 39 Number of survey questions and % of those questions scoring red % Red n/a 0%	95%	CPES 2010	0
CPES (4) 40 and green (7) % Green 11/4 n/a 0%	95% 70%	CPES 2010 CPES 2010	

Definitions: (1) Based on patient postcode and uses the Index of Multiple Deprivation (IMD) 2010; (2) Peer Review (NCPR) source - IV=Internal Verification, PR= Peer Review, EA= Earned Autonomy; (3) The immediate risks or serious concerns may now have been resolved or have an action plan in place for resolution; (4) CPES = Cancer Patient Experience Survey; (5) CNS = Clinical Nurse Specialist; (6) Italic value = total number of survey respondents for tumour group. (7) Based on scoring method used by the Department of Health - red/green scores given for survey questions where the trust was in the lowest or highest 20% of all trusts. Questions with lower than 20 respondents were not given a score. Italic value displayed = the total number of viable survey questions, used as the denominator to calculate the % of red/greens for the trust. n/a = not applicable or not available

Version 1.23 - December 2011

Clinical Aspects - Breast



Using information to improve quality & choice

		
	28	Surgical cases receiving sentinel lymph node biopsy
	29	Day case or one overnight stay surgery
	30	Mastectomy patients receiving immediate reconstruction
Practice	31	Major surgeries in breast cancer patients (including in-situ cases)
	32	Surgical patients receiving mastectomies
	33	Mean length of episode for elective admissions
	34	Mean length of episode for emergency admissions
Outcomes	35	Surgical patients readmitted as an emergency within 28 days
and	36	Q2-Q4 2010/11: First outpatient appointments of all outpatient appointments
Recovery	37	Patients treated surviving at one year (to be included in later profile release)

What do we need for urology services? What is local & specialist?

Summary



- There is a new commissioning landscape in development
- Services will be commissioned at different levels some still to be determined
- Cancer networks and their clinical tumour groups will have a role to play
- The service profiles will be an important element within commissioning support – but need clinical input to fulfil their potential.